Tobam Has $857,000 Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Tobam lessened its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 28.4% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 9,275 shares of the biopharmaceutical company's stock after selling 3,687 shares during the period. Tobam's holdings in Gilead Sciences were worth $857,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. State Street Corp lifted its holdings in shares of Gilead Sciences by 1.4% in the 3rd quarter. State Street Corp now owns 60,171,691 shares of the biopharmaceutical company's stock worth $5,044,795,000 after purchasing an additional 841,776 shares during the last quarter. Wellington Management Group LLP increased its position in Gilead Sciences by 50.9% in the third quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company's stock worth $2,900,921,000 after buying an additional 11,665,593 shares during the period. FMR LLC boosted its holdings in shares of Gilead Sciences by 79.4% during the third quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company's stock valued at $2,780,329,000 after acquiring an additional 14,680,161 shares during the period. Geode Capital Management LLC grew its position in shares of Gilead Sciences by 2.1% during the third quarter. Geode Capital Management LLC now owns 27,540,870 shares of the biopharmaceutical company's stock worth $2,302,119,000 after acquiring an additional 574,421 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Gilead Sciences by 3.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 7,752,975 shares of the biopharmaceutical company's stock worth $650,009,000 after acquiring an additional 224,960 shares during the period. Institutional investors and hedge funds own 83.67% of the company's stock.

Gilead Sciences Stock Down 2.0 %

Shares of GILD traded down $2.00 during mid-day trading on Friday, reaching $96.04. The company's stock had a trading volume of 7,182,199 shares, compared to its average volume of 6,866,207. The company has a market cap of $119.69 billion, a price-to-earnings ratio of 1,067.11, a price-to-earnings-growth ratio of 1.25 and a beta of 0.18. The business has a fifty day moving average of $93.04 and a 200 day moving average of $86.76. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $100.51.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping analysts' consensus estimates of $1.58 by $0.44. The firm had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business's quarterly revenue was up 7.0% compared to the same quarter last year. During the same period last year, the company posted $2.29 EPS. As a group, analysts forecast that Gilead Sciences, Inc. will post 4.35 earnings per share for the current fiscal year.

Insider Activity at Gilead Sciences

In related news, insider Merdad Parsey sold 164,211 shares of the business's stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total value of $15,094,275.12. Following the completion of the sale, the insider now owns 80,801 shares of the company's stock, valued at approximately $7,427,227.92. The trade was a 67.02 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 248,645 shares of Gilead Sciences stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the completion of the sale, the chief financial officer now owns 138,919 shares of the company's stock, valued at $12,886,126.44. This trade represents a 64.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 572,824 shares of company stock valued at $53,611,715. Corporate insiders own 0.16% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on GILD shares. Wolfe Research initiated coverage on Gilead Sciences in a research report on Friday, November 15th. They set an "outperform" rating and a $110.00 price objective for the company. JPMorgan Chase & Co. lifted their price objective on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an "overweight" rating in a research note on Wednesday, January 29th. Piper Sandler increased their target price on shares of Gilead Sciences from $95.00 to $105.00 and gave the company an "overweight" rating in a research report on Thursday, November 7th. Cantor Fitzgerald restated a "neutral" rating and set a $80.00 price target on shares of Gilead Sciences in a research report on Wednesday, December 11th. Finally, Royal Bank of Canada reiterated a "sector perform" rating and issued a $84.00 price objective on shares of Gilead Sciences in a report on Monday, February 3rd. Eleven analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have given a strong buy rating to the stock. According to MarketBeat.com, Gilead Sciences currently has a consensus rating of "Moderate Buy" and a consensus target price of $98.39.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.